Addendum
Addendum to Commission A13-03 (sitagliptin/metformin)
Report documents
-
Addendum
Addendum to Commission A13-03 (sitagliptin/metformin)
Press releases
Gliptins: IQWiG assessed data subsequently submitted by the manufacturer
Studies on sitagliptin also relevant for fixed combination of sitagliptin/metformin: hint of added benefit / vildagliptin still without advantages
Additional information
Federal Joint Committee (G-BA)
2013-10-01 A G-BA decision was published.
Project details
- Project no.
- A13-29
- Commission
- Commission awarded on 07.08.2013 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment
Connected Projects
-
Dossier assessment
Sitagliptin/Metformin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed